Evidence map›Paper›PMID 42406397›Full record

Trial reportJAMA network open2026

Multifocal Noninvasive Deep Brain Stimulation to Enhance Cognition in Mild Cognitive Impairment: A Crossover Trial.

Umberto Nencha, Monika Pupíková, Margaux di Natale, Pablo Maceira-Elvira, Martin Gajdoš, Elena Beanato, Stavriani Skarvelaki, Rebecca Jones, Isabel Ericson, Martin Lamoš and 12 more

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07090681 (Novel Individualized Brain Stimulation, Network-based Approaches to Improve Cognition in Healthy Seniors and Patients With MCI), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07090681 nacompletednot on this map

Novel Individualized Brain Stimulation, Network-based Approaches to Improve Cognition in Healthy Seniors and Patients With MCI

TypeinterventionalSponsorEcole Polytechnique Fédérale de LausanneRan2023 to 2024Enrolled61ConditionsMild Cognitive Impairment (MCI), Healthy AgingArmsActive Control Placebo, tTIS, tTIS + TMS
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Umberto NenchaDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Monika PupíkováNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Margaux di NataleDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Pablo Maceira-ElviraDefitech Chair of Clinical Neuroengineering, INX, EPFL Valais, Clinique Romande de Réadaptation, Sion, Switzerland.
Martin GajdošNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Elena BeanatoDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Stavriani SkarvelakiDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Rebecca JonesDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Isabel EricsonDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Martin LamošNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Andrea NutiDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Fabienne WindelDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
David OndrácekNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Adam ŠimoNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Ela VojtkováNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Klára ŠpunarováNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Vincent AlvarezDepartment of Neurology, Hôpital du Valais, Sion, Switzerland.
Oana SimionescuDepartment of Neurology, Hôpital du Valais, Sion, Switzerland.
Giovanni B FrisoniGeneva Memory Center, Department of Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
Estelle RaffinDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.
Irena RektorováNeuroscience Program, Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Friedhelm C HummelDefitech Chair of Clinical Neuroengineering, Neuro-X Institute, École Polytechnique Fédérale de Lausanne, Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Impairment of working memory (WM), which relies on distributed cortical and subcortical structures, including cerebello-striatal pathways, is a core contributor to functional decline in patients with mild cognitive impairment (MCI) and dementia. Because the striatum is affected early in dementia, whereas the cerebellum remains relatively preserved, the cerebellum may offer support for maintaining striatal function in neurodegenerative diseases. Objective: To evaluate whether sequential cerebellar transcranial magnetic stimulation (TMS) and striatal transcranial temporal interference stimulation (tTIS) enhances WM in patients with MCI, especially those with early striatal degeneration, like MCI with Lewy bodies (MCI-LB). Design, Setting, and Participants: This randomized, quadruple-blind, placebo-controlled, crossover trial was conducted from August 2023 to October 2024 at 1 site in Switzerland and 1 in Czech Republic. Participants included individuals with MCI-LB or amnestic MCI (aMCI) and age-matched healthy controls (HCs). Intervention: Three pseudorandomized single stimulation sessions: (1) cerebellar TMS followed by striatal tTIS, (2) control TMS followed by striatal tTIS, and (3) an active control combining control TMS with control striatal tTIS. Main Outcomes and Measures: The primary outcomes were changes in accuracy and correct answer reaction times in a visual WM task with varying memory loads and distractors. Modulators included resting-state functional connectivity and gray-matter volume in WM-related regions. Linear mixed-effects models were used to examine the main effects of stimulation condition on accuracy and reaction times. Results: Forty-one patients with MCI, including 21 with MCI-LB (16 female [76%]; mean [SD] age, 71.05 [6.84] years) and 20 with aMCI (11 female [55%]; mean [SD] age, 72.30 [7.50] years), and 20 HCs (10 female [50%]; mean [SD] age, 69.5 [4.42] years) were analyzed. In patients with MCI-LB, cerebellar TMS plus striatal tTIS increased accuracy in distractor trials compared with the active control (control TMS plus control tTIS, P < .001; d = -0.77) and striatal tTIS alone (control TMS plus striatal tTIS, P = .004; d = -0.60). Greater accuracy gains were associated with lower putaminal connectivity (r = -0.66; P = .03). In patients with aMCI, cerebellar volumes showed associations with task performance in both distractor trials (cerebellar TMS plus striatal tTIS, R2 = 0.27; P = .02) and high-load trials (control TMS plus striatal tTIS, R2 = 0.24; P = .03), and larger volumes were associated with faster responses; however, significant behavioral differences between active and control stimulation conditions were not observed. No serious adverse events occurred. Conclusions and Relevance: Synergistic dual-target cerebellar TMS and striatal tTIS improved WM in MCI-LB, particularly in patients with lower striatal connectivity, suggesting dual-targeted neuromodulation as a potential therapeutic avenue in neurodegenerative disorders. Trial Registration: ClinicalTrials.gov Identifier: NCT07090681.

Indexed as

Cognitive DysfunctionTranscranial Magnetic StimulationAgedCerebellumCognitive EnhancementCross-Over StudiesFemaleHumansMaleMemory, Short-TermMiddle AgedNeuropsychological Tests

Identifiers

PMID42406397
PMCPMC13338810

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.